Literature DB >> 31513000

Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.

Mohammad P Mahjoob1, Seyed A Sheikholeslami2, Morvarid Dadras3, Hamdollah Mansouri4, Mahshid Haghi5, Mohammadreza Naderian6,7, Leila Sadeghi8, Mohammadreza Tabary9, Isa Khaheshi1.   

Abstract

BACKGROUND: Anthracyclines, a widely used chemotherapy agent with a definite survival improvement, can result in cardiac toxicity presenting with HF (heart failure).
OBJECTIVE: We aim to assess the predictive value of cardiac biomarkers assessment in combination with myocardial two-dimensional strain echocardiography for early detection of cardiac toxicity in patients who underwent Anthracycline-based chemotherapy.
METHODS: Fifty-two consecutive adult patients scheduled to undergo the first course of Anthracycline-based chemotherapy were subjected to the study. All the patients underwent highly sensitive 2D echocardiographic evaluation before the treatment, 4 and 12 weeks after completion of first-course chemotherapy. Longitudinal and segmental strains were measured. Serum levels of High-sensitive cardiac troponin I (hscTn-I) and N-terminal-pro-BNP (NT-proBNP) were also assessed before the initiation and 3 weeks after completion of first-course chemotherapy.
RESULTS: Fifteen patients (28.8%) revealed a decrease in LVEF (Left Ventricular Ejection Fraction) throughout the evaluations, while just 5 patients met the criteria of cardiac toxicity (9.6%). AUC for Global Longitudinal Strain (GLS) ROC curve at 4 weeks of follow-up was calculated to be 0.968. Inferoseptal Systolic Longitudinal Strain (SLS) had the highest AUC value (AUC: 0.934) among different wall SLS. LVESD (Left Ventricular End-Systolic Diameter) at first and second evaluation could predict the risk of cardiac toxicity among LVESD, LVEDD (Left Ventricular End Diastolic Diameter) and LVEDV (Left Ventricular End-Diastolic Volume). Among cardiac biomarkers, hscTnI had higher sensitivity, while NT-proBNP had higher specificity for cardiac toxicity.
CONCLUSION: This study has shown that hs-cTnI with good sensitivity can predict cardiac toxicity in Anthracycline-based chemotherapy receiver. The use of strain with speckle echocardiography method has a prognostic value; however, both longitudinal and segmental strain should be assessed. Lateral and inferoseptal SLS (Segmental Longitudinal Strain) are specific markers of cardiac toxicity in the course of anthracycline-related cardiac toxicity. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Anthracyclines; biomarkers; cardiotoxicity; cardiovascular diseases; echocardiography; heart failure.

Mesh:

Substances:

Year:  2020        PMID: 31513000     DOI: 10.2174/1871529X19666190912150942

Source DB:  PubMed          Journal:  Cardiovasc Hematol Disord Drug Targets        ISSN: 1871-529X


  5 in total

1.  Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction.

Authors:  Biniyam G Demissei; Yong Fan; Yiwen Qian; Henry G Cheng; Amanda M Smith; Kelsey Shimamoto; Natasha Vedage; Hari K Narayan; Marielle Scherrer-Crosbie; Christos Davatzikos; Bonnie Ky
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-03-22       Impact factor: 6.875

Review 2.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

Review 3.  Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.

Authors:  Valentina Bracun; Joseph Pierre Aboumsallem; Peter van der Meer; Rudolf A de Boer
Journal:  Curr Oncol Rep       Date:  2020-06-09       Impact factor: 5.075

4.  Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.

Authors:  Belén Díaz-Antón; Rodrigo Madurga; Blanca Zorita; Samantha Wasniewski; Andrea Moreno-Arciniegas; Beatriz López-Melgar; Natalia Ramírez Merino; Roberto Martín-Asenjo; Patricia Barrio; Maximiliano German Amado Escañuela; Jorge Solís; Francisco Javier Parra Jiménez; Eva Ciruelos; José María Castellano; Leticia Fernández-Friera
Journal:  ESC Heart Fail       Date:  2022-02-02

Review 5.  Oncocardiology: new challenges, new opportunities.

Authors:  Lars Michel; Dirk Schadendorf; Tienush Rassaf
Journal:  Herz       Date:  2020-11       Impact factor: 1.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.